Bing Cao
PhD researcher at the Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University
Data updated
Papers
Trials
Research Footprint
Bing Cao appears in 6 tracked papers (2021–2024), most studied alongside Ketamine, Esketamine and Psilocybin, across Depressive Disorders, Anxiety Disorders and Major Depressive Disorder (MDD).
Most-cited paper: Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis (169 citations).
Frequent co-authors: Jonathan Rosenblat, Roger Ho and Roger McIntyre.
Background & Research
Bing Cao is a researcher affiliated with Southwest University in Chongqing, China, where he appears in the Key Laboratory of Cognition and Personality, Faculty of Psychology. He is coauthor on several psychiatry and psychopharmacology papers focused on ketamine, esketamine, suicidality, biomarkers, and psychedelic analogs. Public author listings identify him as a PhD researcher, but I did not find a definitive personal faculty page or full biography source to verify more detailed training or career history.
Key Impact
He is a recurring coauthor on multiple ketamine and psychedelic-adjacent systematic reviews and mechanistic studies, making him a visible contributor to contemporary rapid-acting antidepressant research.
Collaboration Network
20 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Bing Cao is associated with.
Southwest University
Southwest University is a public comprehensive university in Chongqing, China, with strengths across life sciences, psychology, and interdisciplinary research.
View stakeholder →Brain and Cognition Discovery Foundation
Non-ProfitCanada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.
View stakeholder →